Jazz Pharmaceuticals plc
As of Oct 22, 2026, Jazz Pharmaceuticals is in Stage 3, the topping phase, now in week 3 (since Oct 2, 2026). It closed at $214.65, 18.0% below its 52-week high and below its 200-day average, which is rising.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is JAZZ early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
JAZZ among Biotechnology81st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …81 | JAZZ | Stage 3 · wk 3 | 88 | −8.6% |
Jazz Pharmaceuticals: quick answers
What stage is Jazz Pharmaceuticals in?
As of Oct 22, 2026, Jazz Pharmaceuticals (JAZZ) is in Stage 3, the topping phase. It entered Stage 3 on Oct 2, 2026 and is in week 3. What the four stages mean
Is Jazz Pharmaceuticals in an uptrend?
Its uptrend has stalled. Jazz Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 0.3% below its 200-day average, which is rising.
How far is Jazz Pharmaceuticals from its 52-week high?
Jazz Pharmaceuticals closed at $214.65 on Oct 22, 2026, 18.0% below its 52-week high of $261.62. Its 52-week low is $131.16.
How has Jazz Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Jazz Pharmaceuticals is up 56.1% over the past year and up 24.0% so far in 2026.
Which sector and industry is Jazz Pharmaceuticals in?
Jazz Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.